Tags |
|
|
Links |
|
|
Just Other Articles - Corporate Suicide - Getting Bigger Instead Of Better
Work on becoming better and guess what, you naturally grow bigger. But pushing for
size by itself makes you fatter, not bigger, less specialized and easier to succumb to the
vagaries of internal and external forces. Often you
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
lose what made you viable in the first
place. A chicken that has wings does not mean it can fly. Similarly the big companies
are not necessarily the better ones. Many Asian conglomerates learned this to their
despair in 1997
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
financial crisis - there is no safety net in being big. As a matter of fact,
the bigger they were, the harder they fell. The list includes many of the Asian “giants”
and conglomerates such as the Korean banks, the Hanbo Steel
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
Sammi Steel, Jinro Ltd
and Kia group, the Indonesian state-owned banks Bank Dagang Negara, Bank Bumi
Daya, Bank Negara, Bank Rakyat and Bank Exim and other banks as well as major
corporations in Thailand, Malaysia, the list
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
goes on. All these so-called large major
corporations and banks were mauled badly by the financial crisis in Asia. On the other
hand, the smaller enterprises in Taiwan were largely being spared because of their
nimbleness.
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
Small companies are able to be more nimble and make changes more swiftly than large
ones. This is because small companies do not have to persuade many people and the
communication channels are shorter. Thus the small businesse
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
s are more sensitive to
changes. However, the answer to getting better does not lie entirely on being small as
such companies face financial and resource constraints.
Many construction companies in Singapore are expanding the
Many construction companies in Singapore are expanding the
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
r top lines, however,
clinching sales contracts and projects at a loss. The government tenders are awarded to
the lowest price bidder. As a result, it is quite easy to increase the sales contracts by
dumping the tender price
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
. Owing to the risky nature of construction contracts, which are
fraught with many unexpected costs, projects are delayed and costs overrun. In addition,
many contractors run into problems with liquidated damages because of de
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ay in
completion as well as the payments being delayed. Some even land up in expensive and
protracted litigations, which bring further financial burden to the cash-strapped
construction companies. Getting bigger without any
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
regards for profitability has spelled
the death knell for many contractors.
Research firm Bain & Company reported that over a 10-year period, the five largest drug makers in the United States had grown fivefold to $16.8 billi
Research firm Bain & Company reported that over a 10-year period, the five largest drug makers in the United States had grown fivefold to $16.8 billi
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
on dollars. However, their
operating margins paled by comparison, increasing only a minuscule one percent. The
major setback for profits was the limited return on research and development (R&D)
efforts. Despite the four-fold
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
increase in the R&D expenditure, there was no increase in
new drugs’ approval from the Food and Drug Administration during the same period.
Whilst hopes of profits from the introduction of new drugs dwindled, the pharmaceutica
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
l
industry resorted to mergers to bolster their revenues.
However, such strategy to get bigger led to the dilemma of larger drug companies having to launch three or more new drugs per year just to bring in a moderate annual s
However, such strategy to get bigger led to the dilemma of larger drug companies having to launch three or more new drugs per year just to bring in a moderate annual s
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
les
growth of ten percent. These pharmaceutical companies compounded their problems by
pursuing a strategy of number games – the more drugs to be developed the more chances
of hitting success. As a result, there was little d
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
ifferentiation amongst all the large drug
companies in their drug development. Such strategy is not only costly but also gives the
company a bad name when the much-publicised wonder drugs failed in their trials.
When asked ab
When asked ab
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
ut the design of Virgin’s organisational architecture, Branson replied:
“My philosophy was always that if there were fifty people in a building I would go there
and ask to see the deputy managing director, his deputy sales man
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
ager, his deputy
marketing manager, the deputy press officer”. Branson continued: “You are now the
managing director, the sales manager, the marketing manager, and the press officer of a
new company. I would put them in a ne
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
building. Then again, when that company got
to a certain size – fifty people – I would do the same thing again. Also, if you are given a
card by somebody who says he is the managing director you might, I am afraid take him
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
more seriously than if you were given a card saying that the person was the deputy to the
deputy to the deputy managing director.”
There is nothing wrong with getting bigger, but one has to make sure that it is getting better
There is nothing wrong with getting bigger, but one has to make sure that it is getting better
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.justotherarticles.org.ua/article/13930/justotherarticles-Corporate-Suicide--Getting-Bigger-Instead-Of-Better.html">Corporate Suicide - Getting Bigger Instead Of Better</a>
BB link (for phorums):
[url=http://www.justotherarticles.org.ua/article/13930/justotherarticles-Corporate-Suicide--Getting-Bigger-Instead-Of-Better.html]Corporate Suicide - Getting Bigger Instead Of Better[/url]
Related Articles:
Bad Credit Loan Secrets Most Lenders Don't Want You to Know
Medical Billing - Data Problems
How To Write Eye-Grabbing Headlines That Catapult Your Prospects Into Your Ads
Bookmark it:
|